Design and Evaluation of Nanoparticulate Drug Delivery Systems for Imaging and Treatment of Malignant Brain Tumor

α
Minyahil A. Woldu
Minyahil A. Woldu MSc in Clinical pharmacy
σ
Jimma Likisa Lenjissa
Jimma Likisa Lenjissa
ρ
Gizaw Dabessa Satessa
Gizaw Dabessa Satessa
α Ambo University

Send Message

To: Author

Design and Evaluation of Nanoparticulate Drug Delivery Systems for Imaging and Treatment of Malignant Brain Tumor

Article Fingerprint

ReserarchID

P26P9

Design and Evaluation of Nanoparticulate Drug Delivery Systems for Imaging and Treatment of Malignant Brain Tumor Banner

AI TAKEAWAY

Connecting with the Eternal Ground
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu

Abstract

Malignant brain tumours are one of the most devastating human cancers associated with high mortality and morbidity rates. The median survival of malignant glioma patie-nts ranges between 3 and 16 months and has virtually rema-ined unchanged during the last 3 decades. Difficulties in early detection, local recurrence, and resistance to conventional therapies are the major reasons for failure in malignant brain tumour treatment. The therapy of malignant gliomas is further limited by the inadequate delivery of therapeutic agents to the brain due to the presence of the blood-brain barrier, blood-brain-tumor barrier as well as non-specificity targeting. Nanoparticles (NPs) have drawn increased interest in treating malignant brain tumours due to their potential to act as a vector for brain delivery and to provide tumourspecific detection and treatment. If designed appropriately, NPs may act as a drug vehicle able to target tumor tissues or cells, and protect the drug from inactivation during its transport. The aim of this article was to provide brief overview of nanoparticulate drug delivery systems for imaging and treatment of brain cancer and to evaluate their safety in clinical use. Besides invasive physical methods to bypass or disrupt the BBB and/or BBTB, other methods like pharmacological and physio-logic approach are possible.

References

47 Cites in Article
  1. Alessandra Pavesio (2006). Regenerative Medicine.
  2. C Hadjipanayis,A Bouras,S Chang (2013). Applications of Multifunctional Nanoparticles in Malignant Brain Tumours.
  3. Y Cheng,R Morshed,B Auffinger,A Tobias,M Lesniak (2013). Multifunctional nanoparticles for brain tumor imaging and therapy.
  4. Gann Ting (2009). Cancer Nanotargeted Radiopharmaceuticals for Tumor Imaging and Therapy.
  5. L Muldoon,P Tratnyek,P Jacobs,N Doolittle,G Christoforidis (2006). Imaging and Nanomedicine for Diagnosis and Therapy in the Central Nervous System: Report of the Eleventh Annual Blood-Brain Barrier Disruption Consortium Meeting.
  6. Tennyson Joseph D Meyers,Clemens Doane,James Burda,Basilion (2013). Nanoparticles for imaging and treating brain cancer.
  7. M Amiji (2006). Nanotechnology for Cancer Therapy.
  8. Natalie Praetorius,Tarun Mandal (2007). Engineered Nanoparticles in Cancer Therapy.
  9. Juillerat-Jeanneret L (2008). The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drugnanoparticles?.
  10. S Moghimi,A Hunter,J Murray (2005). Nanomedicine: current status and future prospects.
  11. Loredana Serpe (2006). Conventional Chemotherapeutic Drug Nanoparticles for Cancer Treatment.
  12. R Saha,S Vasanthakumar,G Bende,M Snehalatha (2010). Nanoparticulate drug delivery systems for cancer chemotherapy.
  13. Frank Alexis,Eric Pridgen,Robert Langer,Omid Farokhzad (2010). Nanoparticle Technologies for Cancer Therapy.
  14. Yashwant Pathak,Deepak Thassu,Michel Deleers (2009). Pharmaceutical Applications of Nanoparticulate Drug-Delivery Systems.
  15. A Guyton,Je (2005). Sports Physiology.
  16. Massimo Masserini (2013). Nanoparticles for Brain Drug Delivery.
  17. H Sarin,A Kanevsky,H Wu,K Brimacombe,S Fung,Sa (2008). Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells.
  18. F Giulio,Lawrence Paciotti,Tamarkin (2007). Nanoparticulate Drug Delivery Systems.
  19. Scenihr) Scoeanihr (2006). Guide for Assessment of Adventitious Agents in Tissue Engineered Medical Products (TEMPs).
  20. Amrita Dikpati,Madgulkar,J Sanjay,Kshirsagar,Bhalekar,Chahal,As (2012). Targeted Drug Delivery to CNS using Nanoparticles.
  21. K Swatantra,Aditi Kushwaha,A Rastogi,Satyawan Rai,Singh (2012). Novel Drug Delivery System for Anticancer Drug.
  22. Jun Wu,Xiaobin Zhao,Robert Lee (2007). Lipid-Based Nanoparticulate Drug Delivery Systems.
  23. Oktay Tacar,Pornsak Sriamornsak,Crispin Dass (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems.
  24. Regulon (2009). BBB (blood‐brain barrier).
  25. S Gelperina,A Khalansky,I Skidan,Z Smirnova,A Bobruskin (2002). Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma.
  26. J Kreuter (2001). Nanoparticulate systems for brain delivery of drugs.
  27. Nazila Kamaly,Zeyu Xiao,Pedro Valencia,Aleksandar Radovic-Moreno,Omid Farokhzad (2011). Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.
  28. Bärbel Volker Wagner,Sibylle Hüsing,Anne-Katrin Gaisser,Bock (2006). Science in trade disputes related to potential risks: comparative case studies. IPTS technical report series EUR 21301 EN, European Commission Joint Research Centre / IPTS Institute for Prospective Technological Studies, Brussels/Luxembourg.
  29. Ernest Azzopardi,Elaine Ferguson,David Thomas (2013). The enhanced permeability retention effect: a new paradigm for drug targeting in infection.
  30. H Choi,W Liu,P Misra,E Tanaka,J Zimmer (2007). Renal clearance of quantum dots.
  31. Y Pathak,D Thassu,M Deleers (2007). Pharmaceutical Applications of Nanoparticulate Drug-Delivery Systems.
  32. Luca Costantino,Diana Boraschi (2012). Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?.
  33. Hai He,Yan Li,Xin-Ru Jia,Ju Du,Xue Ying,Wan-Liang Lu,Jin-Ning Lou,Yan Wei (2011). PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors.
  34. H Yan,L Wang,J Wang,X Weng,H Lei (2012). Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier.
  35. R Letfullin,C Iversen,G Tf (2011). Modeling nanophotothermal therapy: kinetics of thermal ablation of healthy and cancerous cell organelles and gold nanoparticles.
  36. C Hadjipanayis,R Machaidze,M Kaluzova,L Wang,A Schuette (2010). EGFRvIII antibodyconjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.
  37. N Khlebtsov,L (2011). Review Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies.
  38. A Freitas,J (2005). Current Status of Nanomedicine and Medical Nanorobotics Institute for Molecular Manufacturing, Palo Alto, California, USA.
  39. X Gao,L Yang,J Petros,F Marshall,J Simons (2005). Review In vivo molecular and cellular imaging with quantum dots.
  40. Ja Park,Myung Baek,Eun Choi,Seungtae Woo,Joo Kim,Tae Kim,Jae Jung,Kwon Chae,Yongmin Chang,Gang Lee (2009). Paramagnetic Ultrasmall Gadolinium Oxide Nanoparticles as Advanced <i>T</i><sub>1</sub> MRI Contrast Agent: Account for Large Longitudinal Relaxivity, Optimal Particle Diameter, and <i>In Vivo</i> <i>T</i><sub>1</sub> MR Images.
  41. Omid Veiseh,Conroy Sun,Jonathan Gunn,Nathan Kohler,Patrik Gabikian,Donghoon Lee,Narayan Bhattarai,Richard Ellenbogen,Raymond Sze,Andrew Hallahan,Jim Olson,Miqin Zhang (2005). Optical and MRI Multifunctional Nanoprobe for Targeting Gliomas.
  42. C Hadjipanayis,R Machaidze,M Kaluzova,L Wang,A Schuette (2010). EGFRvIII antibodyconjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.
  43. R Gref,M Lück,P Quellec,M Marchand,E Dellacherie,S Harnisch,T Blunk,R Müller (2000). ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption.
  44. Fernanda Sousa,Subhra Mandal,Chiara Garrovo,Alberto Astolfo,Alois Bonifacio,Diane Latawiec,Ralf Menk,Fulvia Arfelli,Sabine Huewel,Giuseppe Legname,Hans-Joachim Galla,Silke Krol (2010). Functionalized gold nanoparticles: a detailed in vivo multimodal microscopic brain distribution study.
  45. Rachela Popovtzer,Ashish Agrawal,Nicholas Kotov,Aron Popovtzer,James Balter,Thomas. Carey,Raoul Kopelman (2008). Targeted Gold Nanoparticles Enable Molecular CT Imaging of Cancer.
  46. Susan Foy,Rachel Manthe,Steven Foy,Sanja Dimitrijevic,Nishanth Krishnamurthy,Vinod Labhasetwar (2010). Optical Imaging and Magnetic Field Targeting of Magnetic Nanoparticles in Tumors.
  47. M Dyer,M Hinchcliffe,P Watts,J Casille,I Jabbal-Gill (2002). Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Minyahil A. Woldu. 2014. \u201cDesign and Evaluation of Nanoparticulate Drug Delivery Systems for Imaging and Treatment of Malignant Brain Tumor\u201d. Global Journal of Science Frontier Research - G: Bio-Tech & Genetics GJSFR-G Volume 14 (GJSFR Volume 14 Issue G1): .

Download Citation

Issue Cover
GJSFR Volume 14 Issue G1
Pg. 15- 25
Journal Specifications

Crossref Journal DOI 10.17406/GJSFR

Print ISSN 0975-5896

e-ISSN 2249-4626

Version of record

v1.2

Issue date

May 7, 2014

Language
en
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 4722
Total Downloads: 2419
2026 Trends
Related Research

Published Article

Malignant brain tumours are one of the most devastating human cancers associated with high mortality and morbidity rates. The median survival of malignant glioma patie-nts ranges between 3 and 16 months and has virtually rema-ined unchanged during the last 3 decades. Difficulties in early detection, local recurrence, and resistance to conventional therapies are the major reasons for failure in malignant brain tumour treatment. The therapy of malignant gliomas is further limited by the inadequate delivery of therapeutic agents to the brain due to the presence of the blood-brain barrier, blood-brain-tumor barrier as well as non-specificity targeting. Nanoparticles (NPs) have drawn increased interest in treating malignant brain tumours due to their potential to act as a vector for brain delivery and to provide tumourspecific detection and treatment. If designed appropriately, NPs may act as a drug vehicle able to target tumor tissues or cells, and protect the drug from inactivation during its transport. The aim of this article was to provide brief overview of nanoparticulate drug delivery systems for imaging and treatment of brain cancer and to evaluate their safety in clinical use. Besides invasive physical methods to bypass or disrupt the BBB and/or BBTB, other methods like pharmacological and physio-logic approach are possible.

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Design and Evaluation of Nanoparticulate Drug Delivery Systems for Imaging and Treatment of Malignant Brain Tumor

Minyahil A. Woldu
Minyahil A. Woldu Ambo University
Jimma Likisa Lenjissa
Jimma Likisa Lenjissa
Gizaw Dabessa Satessa
Gizaw Dabessa Satessa

Research Journals